UPM Biomedicals launches FibGel™ the world's first injectable nanocellulose hydrogel for medical devices
HELSINKI, Oct. 24, 2024 /PRNewswire/ -- UPM Biomedicals, the forerunner in producing high quality nanofibrillar cellulose for medical and life science applications, today announces the launch of FibGel™— a natural injectable hydrogel for permanent implantable medical devices. FibGel is a nanofibrillar cellulose hydrogel made from birch wood cellulose and water only, offering a safe, sustainable and biocompatible alternative for medical device developers. Designed and manufactured under ISO 13485 standards in Finland and designed for medical applications, FibGel is poised to transform the fields of soft tissue repair, orthopaedics, regenerative medicine and more.
Unlike synthetic and animal-derived hydrogels, FibGel is a natural hydrogel— manufactured from renewable and responsibly-sourced Finnish birch wood—offering a safe, sustainable, animal-free solution. As a stable, non-degradable material, FibGel is designed for long-lasting use in the human body without causing adverse immune reactions or the formation of fibrotic capsules common to animal-derived and plastic-based alternatives.
FibGel is customizable owing to its tunable properties that allow adjustable stiffness and the incorporation of additional components. This flexibility enables tailored solutions for varying clinical needs and holds promise in a wide range of medical applications, including soft tissue repair, orthopaedic treatments, aesthetics, drug delivery, and cell transplantation. With FibGel's biological safety evaluations in accordance with ISO 10993, it is an ideal component for companies developing medical devices for use in various soft tissue repair and orthopaedic applications. Our first partners are planning their initial clinical investigations based on FibGel technology in 2025.
UPM has extensive expertise in developing sustainable, animal-free hydrogels and rigorous testing has demonstrated FibGel's biocompatibility. Based on the preclinical studies, its stability supports permanent implant and one-time injection applications, critical for patient convenience and saving health care providers' time. FibGel is highly tunable, easy to use and remains injectable even at high stiffness thanks to its shear thinning properties.
"We are thrilled to be the first company to develop plant-based nanocellulose for use in medical devices. It enables minimally invasive procedures, which compared to surgery means rapid patient recovery," commented Johana Kuncová-Kallio, Director of UPM Biomedicals.
"In 2020 we launched our own FibDex® topical medical device (MDD/MDR, class IIb) for advanced wound care, which has been used to successfully treat several hundreds of patients. Now, with the launch of FibGel, we can provide the same safe, sustainable, animal-free material in an injectable hydrogel form to medical device companies. Based on our pre-clinical evidence for FibGel, our initial partners have been able to speed up their device development and are now planning to start the clinical phase in 2025. We aim to partner with more companies interested in developing new solutions in the areas of soft tissue repair, joint and disk repair, wound care, drug delivery and cell therapy based on FibGel technology."
FibGel also benefits from robust temperature stability, enabling it to be handled and stored at room temperature for ease of use and quick preparation. It's long 18-month minimum shelf life delivers reliable performance without special storage conditions, reducing logistical challenges.
For more information, please visit www.upmbiomedicals.com.
For further information please contact:
Johana Kuncová-Kallio, Director, UPM Biomedicals, tel. +358 40 612 6300
UPM, Media Relations
Mon-Fri 9:00–16:00 EEST
tel. +358 40 588 3284
media@upm.com
UPM Biomedicals
UPM Biomedicals is the forerunner in producing high quality nanofibrillar cellulose for medical and life science applications. More than 300 patents protect the existing and future products that rely on the Finnish birch pulp. We actively collaborate with universities, research centers and key industrial partners on future innovations and products in the field of high throughput drug screening, personalized medicine, advanced cell therapies, 3D bioprinting, tissue engineering and advanced wound care.
UPM
We deliver renewable and responsible solutions and innovate for a future beyond fossils across six business areas : UPM Fibres, UPM Energy, UPM Raflatac, UPM Specialty Papers, UPM Communication Papers and UPM Plywood. As the industry leader in responsibility, we are committed to the UN Business Ambition for 1.5°C and the science-based targets to mitigate climate change. We employ 16,600 people worldwide and our annual sales are approximately EUR 10.5 billion. Our shares are listed on Nasdaq Helsinki Ltd. UPM Biofore – Beyond fossils. www.upm.com
Follow UPM on X | LinkedIn | Facebook | YouTube | Instagram | #UPM #biofore #beyondfossils
This information was brought to you by Cision http://news.cision.com
Share this article